In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Risk associated with Omicron (medRxiv) Expansion of monoclonal EUA (FDA) Neutralization of Omicron by sera (medRxiv) Third dose sera neutralize Omicron (Pfizer) Monoclonals authorized for PreP (FDA) Patient outcomes after monoclonals (Open Forum Inf Dis) Subcutaneous or intramuscular monoclonals (medRxiv) WHO does not recommend convalescent serum (WHO) Immunomodulation and thromboembolic risk (J Clin Med) Long COVID after infection of vaccinated (medRxiv) Letters read on TWiV 840 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]